Search
Three states legalized adult recreational marijuana use in 2022 and the use of therapeutic psychedelics is gaining acceptance as two more states this year legalized their use, some cities have decriminalized their use and more states may legalize them in the future. But while use of these drugs may...
Cannabis Law Partner Zachary Kobrin in Fort Lauderdale shared with Law.com his 2023 cannabis law predictions, including more consolidation and perhaps more Congressional consternation in the year ahead. Kobrin was quoted: “2023 will be a year of consolidation and reduction for the cannabis industry...
Work Product Protection for Patient Safety Information Charles Kelly, MS, partner, at Saul Ewing LLP, will walk attendees through two important pieces of legislation that protect healthcare workers: the Patient Safety and Quality Improvement Act of 2005, which ensures federal privilege and...
On December 2, 2022, the Office for Civil Rights (“ OCR”) and the Substance Abuse and Mental Health Services Administration (“ SAMHSA”) within the U.S. Department of Health and Human Services (“ HHS”) issued a Notice of Proposed Rulemaking (“ NPRM”) to revise the Confidentiality of Substance Use...
Neither shots nor pills will immunize smaller medical, dental, chiropractic, and physical therapy practices, surgery centers, and other healthcare concerns from compliance with the looming (and burdensome) reporting obligations imposed on them if they are “reporting companies” under the federal...
Effective November 16, 2022, New Jersey will impose additional requirements when a ‘health care entity’ is sold or undergoes a change in control. The changes are the result of the enactment of S-315, on August 18, 2021. What You Need to Know: New Jersey enacted a statute that will impose additional...
In this exciting presentation, Jonathan Havens, a former FDA regulator and Capitol Hill staffer, will discuss the current hemp and cannabinoid and regulatory landscapes, and how they might change.
In this exciting presentation, Jonathan Havens, a former FDA regulator and Capitol Hill staffer, will discuss the current hemp and cannabinoid and regulatory landscapes, and how they might change.
In this exciting presentation, Jonathan Havens, a former FDA regulator and Capitol Hill staffer, will discuss the current hemp and cannabinoid and regulatory landscapes, and how they might change.
In a Cannabis Business Times article, Partner Zachary Kobrin in Fort Lauderdale shared predictions for the newly legalized adult-use markets in Maryland and Missouri, as well as how the federal landscape may shift in the next year. On the topic of the SAFE Banking Act, Kobrin said it is “the most...
In this exciting presentation, Jonathan Havens, a former FDA regulator and Capitol Hill staffer, will discuss the current hemp and cannabinoid and regulatory landscapes, and how they might change.